Nektar Therapeutics is a clinical-stage company developing rezpegaldesleukin, an injected drug that expands regulatory T cells, for atopic dermatitis and alopecia areata; it is not approved.
Nektar's case rests on rezpegaldesleukin, an IL-2 pathway drug designed to expand regulatory T cells, which met its primary endpoint in the Phase 2b REZOLVE-AD trial in atopic dermatitis. Three Phase 3 ZENITH AD trials have started, with initial data expected in mid-2028 and a first BLA planned in 2029. A jury awarded Nektar $90 million plus interest from Eli Lilly, subject to appeal, and cash of $1,023.4 million lasts into the third quarter of 2028.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: ZENITH AD repeats the Phase 2b result
Does rezpegaldesleukin beat placebo in Phase 3 by a margin like Phase 2b?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Rezpegaldesleukin's Phase 3 atopic dermatitis program is under way, with data in mid-2028 and cash into Q3 2028
Rezpegaldesleukin's Treg-expansion durability claim in atopic dermatitis must hold in Phase 3 against a market Dupixent already dominates
REZOLVE-AD 52-week maintenance phase data
REZOLVE-AD Phase 2b primary endpoint met in atopic dermatitis
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Blood cancers, Lung cancer, Other cancers, Neurology and pain, Obesity, diabetes and heart disease, Skin diseases, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
23 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.